dipalmitoylphosphatidic acid has been researched along with Experimental Mammary Neoplasms in 1 studies
dipalmitoylphosphatidic acid: RN given refers to parent cpd without isomeric designation
dihexadecanoyl phosphatidic acid : A phosphatidic acid in which the phosphatidyl acyl groups are both palmitoyl (hexadecanoyl).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Zhou, Z | 1 |
| Yao, Y | 1 |
| Dai, J | 1 |
| Zhou, D | 1 |
| Wang, L | 1 |
| Zhang, QQ | 1 |
1 other study available for dipalmitoylphosphatidic acid and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; C | 2018 |